Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Capecitabine + Camrelizumab + Apatinib in Advanced Pancreatic Cancer
NCT06759090Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, Rivoceranib and capecitabine in pancreatic adenocarcinoma (PDAC), sponsored by Zhejiang University. Primary endpoints: Objective Response Rate at 18 months, Disease Control Rate at 18 months and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibcapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06759090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759090.